This is the estrogen receptor. Women typically have a lot of the swimming around in their cytosol. Once estrogen binds, the complex moves to the DNA and transcription of the corresponding genes start.
In this picture there is only the ligand binding domain. They couldn't crystallise the whole protein because it was too flexible. Instead of showing different domains they chose to show the same domain three times. Alright: it's because of the crystallisation and XRD technique. The unit cell happens to have 3 unique molecules.
In this picture there is only the ligand binding domain. They couldn't crystallise the whole protein because it was too flexible. Instead of showing different domains they chose to show the same domain three times. Alright: it's because of the crystallisation and XRD technique. The unit cell happens to have 3 unique molecules.

The small green things are the estrogens bound to their respective estrogen receptors. If you are trying to find a new drug that targets the receptor, these so called ligands and their binding sites are the most interesting part. The goal of in-silico drug design is screening a large library of molecules to find different molecules that also bind to a given receptor.
If you don't know what the structure of a protein looks like but you have the structure of similar proteins, you can go for homology modeling.
Once you have the structure of the binding site you try to dock ligands that will probably fit in your structure. First you have to find the right geometry of the ligand. After you have done that you have to score the docking, i.e. estimate the change in free energy of the docking process. This is rather difficult because there is no zero point energy to compare your docking pose with and because you have to include entropic effects.

After excitation (γ means "photon" [2]) the cis-doublebond becomes a single bond. Because of that it stretches out. Now there is an ecliptical single bond with weak π-conjugation. It spontaniously rotates.







